trending Market Intelligence /marketintelligence/en/news-insights/trending/05AbhiF2ViO6mlHBFjSH1Q2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Clearside Biomedical seeks US FDA approval for eye drug

Video

Climate Credit Analytics: Linking climate scenarios to financial impacts

Blog

Global M&A Infographic Q1 2021

Blog

Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge

Blog

COVID-19 Impact & Recovery: Private Equity


Clearside Biomedical seeks US FDA approval for eye drug

Clearside Biomedical Inc. submitted a new drug application with the U.S. Food and Drug Administration seeking approval for its eye drug Xipere.

The Alpharetta, Ga.-based drugmaker is seeking the regulator's nod for Xipere as a treatment for macular edema — a build-up of fluid in a part of the eye — associated with uveitis, or the inflammation of the eye's middle layer.

Uveitis affects about 350,000 patients in the U.S. and over a million globally, Clearside said in a news release.